Clincosm LogoSign in Get a demo

Retinal Vessel Diameter in Branch Retinal Vein Occlusion

Sponsor
Kyungpook National University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02215109
Collaborator
(none)
25
Enrollment
1
Location
52
Duration (Months)
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    25 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection
    Study Start Date :
    Apr 1, 2012
    Actual Primary Completion Date :
    Jul 1, 2016
    Actual Study Completion Date :
    Aug 1, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    BRVO, Retinal vessel diameter

    The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.

    Outcome Measures

    Primary Outcome Measures

    1. Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion [0, 1, 3, and 6 months]

      To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Best-corrected visual acuity less than 20/40

    • Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography

    Exclusion Criteria:

    • Patients with recurrent BRVO

    • History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation

    • Patients with diabetes or dyslipidemia

    • IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy

    • High myopia (<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries

    • Co-existing retinal disease other than BRVO

    • Corneal diseases include ulcer, keratoconus and a history of corneal laceration

    • Cataract and other media opacities resulting in visual impairment or poor fundus images

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dong Ho Park Daegu Kyungsangpookdo Korea, Republic of 700-721

    Sponsors and Collaborators

    • Kyungpook National University Hospital

    Investigators

    • Principal Investigator: Dong Ho Park, M.D., Kyungpook National University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dong Ho Park, Clinical professor, Kyungpook National University Hospital
    ClinicalTrials.gov Identifier:
    NCT02215109
    Other Study ID Numbers:
    • KNUHOPH2014-01
    First Posted:
    Aug 13, 2014
    Last Update Posted:
    Aug 30, 2016
    Last Verified:
    Aug 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:
    Retinal Vein Occlusion

    Study Results

    No Results Posted as of Aug 30, 2016